SE0302192D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- SE0302192D0 SE0302192D0 SE0302192A SE0302192A SE0302192D0 SE 0302192 D0 SE0302192 D0 SE 0302192D0 SE 0302192 A SE0302192 A SE 0302192A SE 0302192 A SE0302192 A SE 0302192A SE 0302192 D0 SE0302192 D0 SE 0302192D0
- Authority
- SE
- Sweden
- Prior art keywords
- novel compounds
- solvate
- meanings
- pro
- therapy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/26—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302192A SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Novel compounds |
| EP04749189A EP1654217A1 (en) | 2003-08-08 | 2004-07-28 | 2- adamantyl derivatives as p2x7 receptor antagonists. |
| US10/567,711 US20070037830A1 (en) | 2003-08-08 | 2004-07-28 | 2-Adamantyl derivatives as p2X7 receptor antagonists. |
| PCT/SE2004/001154 WO2005014529A1 (en) | 2003-08-08 | 2004-07-28 | 2- adamantyl derivatives as p2x7 receptor antagonists. |
| JP2006522527A JP2007501782A (ja) | 2003-08-08 | 2004-07-28 | P2x7受容体アンタゴニストとしての2−アダマンチル誘導体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302192A SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0302192D0 true SE0302192D0 (sv) | 2003-08-08 |
Family
ID=27800872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0302192A SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Novel compounds |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070037830A1 (xx) |
| EP (1) | EP1654217A1 (xx) |
| JP (1) | JP2007501782A (xx) |
| SE (1) | SE0302192D0 (xx) |
| WO (1) | WO2005014529A1 (xx) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| EP1644041A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| EP1644042A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| JP2007501270A (ja) * | 2003-05-29 | 2007-01-25 | アストラゼネカ・アクチエボラーグ | P2X7受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物 |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| WO2007008157A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 2 |
| US20080207577A1 (en) * | 2005-07-11 | 2008-08-28 | Astrazeneca Ab | Combination I |
| KR20090094336A (ko) | 2006-11-27 | 2009-09-04 | 하. 룬트벡 아크티에 셀스카브 | 헤테로아릴 아미드 유도체 |
| EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
| CA2682925A1 (en) | 2007-04-10 | 2008-10-16 | David C. Ihle | Heteroaryl amide analogues |
| AU2008275891B2 (en) * | 2007-07-19 | 2013-10-10 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
| WO2009023623A1 (en) * | 2007-08-10 | 2009-02-19 | H, Lundbeck A/S | Heteroaryl amide analogues |
| EP2105164B1 (en) | 2008-03-25 | 2011-01-12 | Affectis Pharmaceuticals AG | Novel P2X7R antagonists and their use |
| US8153808B2 (en) | 2008-12-23 | 2012-04-10 | Roche Palo Alto Llc | Dihydropyridone amides as P2X7 modulators |
| ATE541832T1 (de) | 2009-04-14 | 2012-02-15 | Affectis Pharmaceuticals Ag | Neuartige p2x7r-antagonisten und ihre verwendung |
| EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| EP2931717B1 (en) | 2012-12-12 | 2016-12-07 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as p2x7 receptor antagonists |
| CA2891499C (en) | 2012-12-18 | 2021-07-06 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| KR102035463B1 (ko) * | 2018-02-14 | 2019-11-26 | 연세대학교 산학협력단 | 암 줄기세포의 치료용 약학 조성물 |
| IL277602B2 (en) * | 2018-03-29 | 2024-06-01 | Centre Nat Rech Scient | P2RX7 modulators in therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471491A (en) * | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) * | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| US4349552A (en) * | 1978-10-30 | 1982-09-14 | Fujisawa Pharmaceutical Company, Ltd. | 5-Fluorouracil derivatives, and their pharmaceutical compositions |
| US4751292A (en) * | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| US5399564A (en) * | 1991-09-03 | 1995-03-21 | Dowelanco | N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides |
| KR20000065219A (ko) * | 1996-05-20 | 2000-11-06 | 마르크 젠너 | 티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드 |
| EP1037878A2 (en) * | 1997-11-21 | 2000-09-27 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| TR200102911T2 (tr) * | 1999-04-09 | 2002-01-21 | Astrazeneca Ab | Adamantan türevleri. |
| SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| GB0013737D0 (en) * | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| PT1406628E (pt) * | 2001-07-02 | 2006-06-30 | Akzo Nobel Nv | Derivados de tera-hidroquinolina |
| WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| SE0103836D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| US6908939B2 (en) * | 2001-12-21 | 2005-06-21 | Galderma Research & Development S.N.C. | Biaromatic ligand activators of PPARγ receptors |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300445D0 (sv) * | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
| SE0300480D0 (sv) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| EP1644042A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| EP1644041A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| JP2007501270A (ja) * | 2003-05-29 | 2007-01-25 | アストラゼネカ・アクチエボラーグ | P2X7受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物 |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
-
2003
- 2003-08-08 SE SE0302192A patent/SE0302192D0/xx unknown
-
2004
- 2004-07-28 WO PCT/SE2004/001154 patent/WO2005014529A1/en not_active Ceased
- 2004-07-28 EP EP04749189A patent/EP1654217A1/en not_active Withdrawn
- 2004-07-28 JP JP2006522527A patent/JP2007501782A/ja active Pending
- 2004-07-28 US US10/567,711 patent/US20070037830A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005014529A1 (en) | 2005-02-17 |
| EP1654217A1 (en) | 2006-05-10 |
| US20070037830A1 (en) | 2007-02-15 |
| JP2007501782A (ja) | 2007-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0302192D0 (sv) | Novel compounds | |
| TW200613243A (en) | Novel compounds | |
| DE602004024375D1 (de) | Carboxamidderivate | |
| SE0302811D0 (sv) | Novel compounds | |
| SE0200920D0 (sv) | Novel compounds | |
| SE0202539D0 (sv) | Compounds | |
| MXPA05008690A (es) | Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| SE0104140D0 (sv) | Novel Compounds | |
| SE0301700D0 (sv) | Novel compounds | |
| MXPA05009985A (es) | Ligandos de receptores de canabinoides. | |
| MY139302A (en) | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
| ATE316083T1 (de) | Adamantanderivate | |
| IS6658A (is) | Ný efnasambönd | |
| TW200610527A (en) | Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | |
| TW200800999A (en) | Novel compounds | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| IS6520A (is) | Ný efnasambönd | |
| MY136430A (en) | N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation | |
| SE0400284D0 (sv) | Novel compounds | |
| SE0302139D0 (sv) | Novel compounds | |
| GB0415365D0 (en) | Pyrimidine derivatives | |
| SE0401762D0 (sv) | Novel compounds | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| TW200604197A (en) | New compounds | |
| SE0402925D0 (sv) | Novel Compounds |